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Cough is a common symptom in people who develop interstitial lung diseases (ILD). The pathological features of
the ILDs are many and varied suggesting that the cause of cough may also vary with each disease. This article
reviews what is currently known about cough in sarcoidosis and idiopathic pulmonary fibrosis; two of the
commonest ILDs. It also outlines some of the theories which have been proposed to explain why cough develops
in these conditions and describes what little is known about how to treat it.Sarcoidosis
Sarcoidosis is a multi-system disorder of unknown aeti-
ology which is characterised histologically by the infiltra-
tion of affected tissue by non-caseating granulomatous
inflammation. Whilst any part of the body can be involved,
sarcoidosis typically affects hilar and mediastinal lymph
nodes, the lung interstitium and bronchial epithelum. Less
commonly, the upper respiratory tract, pleura and pul-
monary vessels may be involved. A number of epidemio-
logical studies have investigated the prevalence of cough
in people with sarcoidosis and whilst it appears rare in
Japan, it is common in other parts of the world where the
prevalence is between 30 and 50% (Table 1) [1-3].
Whilst little is known about the mechanisms by which
sarcoidosis causes cough [4], clinical observation sug-
gests that neither massive hilar and mediastinal lymph-
adenopathy nor interstitial infiltration are, in themselves,
sufficient to cause significant cough (Figure 1). Perhaps
more important is the recognition that sarcoidosis is
often a bronchocentric disease associated with granu-
lomatous inflammation of the airways [5]. This is not al-
ways apparent on radiological imaging and is best
appreciated by fibreoptic bronchoscopy although it may
sometimes only be detected by histological examination
of endobronchial biopsies which otherwise have a nor-
mal macroscopic appearance (Figure 2).
One retrospective study from China supports the link
between granulomatous inflammation of the airways and
cough in sarcoidosis. This study compared respiratoryCorrespondence: Kim.Harrison@wales.nhs.uk
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reproduction in any medium, provided the orsymptoms in 87 patients who had undergone tracheal
biopsy and found that significantly more (92%) of those
who had granulomatous tracheitis complained of cough
compared with those (49%) who had normal tracheal bi-
opsies [6]. This study did not report on the broncho-
scopic appearances of the bronchial mucosa nor on the
histological appearances of bronchial biopsies but it
seems plausible that cough in the latter group may have
been caused by inflammation of the bronchi or smaller
airways without tracheal involvement.
Sarcoidosis of the upper respiratory tract (SURT) occurs
in approximately 5% of cases and may variably affect the
larynx, epiglottis, arytenoids, the aryepiglottic folds and
vocal chords as well as the nasal mucosa and sinuses [7].
There are no epidemiological studies of cough in relation
to SURT but given the sensitivity of the glottis to mechan-
ical and chemical stimulation in normal subjects it seems
likely that inflammatory change in and around the larynx
would increase cough reflex sensitivity.
The enhanced cough reflex observed in people with
saroidosis is likely initiated by sensory fibres of the vagus
nerve that innervate the airways and larynx which have
become sensitised by granulomatous inflammation. The
precise mechanism by which this occurs is uncertain.
However, it is interesting that Ricci and co-workers dem-
onstrated that a number of non-neuronal cell types can
express neurotrophins and their receptors in normal
human lung [8]. These include bronchial and alveolar
epithelial cells, bronchial glands and mesenchymal cells
of the interstitium as well as lymphocytes and macro-
phages. These observations led them to suggest that
neurotrophins may play a role in the regulation of normalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Epidemiological studies of the prevalence of
cough in sarcoidosis






Pietinalho (1996) [1] 571 Finland 41 59% 33%
Pietinalho (1996) [1] 686 Japan 30 55% 3%
Kiter (2011) [2] 293 Turkey 44 67% 52%
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of lung disease [8]. In a subsequent study they demon-
strated that alveolar macrophages and lymphocytes de-
rived from bronchoalveolar lavage fluid from patients with
sarcoidosis showed enhanced expression of neurotrophins
and their receptors [9]. These findings were confirmed by
Dagnell and coworkers who went on to show that sarcoid
granulomas and alveolar macrophages stained for the
neurotrophins Nerve Growth Factor (NGF), Brain-
Derived Neurotrophic Factor (BDNF) and Neurotrophin-
3 (NT3) as well as their receptors TrkA, TrkB and TrkC
[10,11]. Thus, increased levels of neurotrophins occur at
sites of granulomatous inflammation in the airways of
patients with sarcoidosis - a location where they could
potentially modulate sensory nerve proliferation and/or
differentiation to enhance neuronal sensitivity and cause
cough.
Occasional, unusual manifestations of sarcoidosis have
been described which cause patients to present with the
symptom of cough. These include granulomatous infil-
tration of the pulmonary veins causing pulmonary veno-
occlusive disease with engorgement of airway epithelium
and sarcoidosis affecting the vagus nerve at the level of
the jugular foramen causing vocal cord palsy and cough
[12,13].
There have been no randomised, placebo-controlled
clinical trials which have investigated the effect of anyFigure 1 a Chest radiograph showing massive hilar and mediastinal l
nodular infiltration of the lung interstitium. Neither of these patients copharmacological treatment specifically for cough in sar-
coidosis. However, clinical observation suggests that
when used in an appropriate clinical setting such as
progressive interstitial lung disease, oral corticosteroid
therapy has a beneficial effect on cough when it is a
troublesome accompanying symptom. One double-blind,
placebo-controlled study of inhaled corticosteroids in
newly diagnosed patients with pulmonary sarcoidosis
reported an improvement in global symptom score
which included cough [14]. However, the placebo group
were more symptomatic at the start of the study and the
authors reported that both cough and fatigue persisted
in a number of patients on active treatment as well as
placebo. Thus whilst accepting the evidence is weak, a
systemic review of steroid therapy in sarcoidosis has sug-
gested that inhaled corticosteroids could be offered to
selected patients with cough [15].
Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is the commonest
form of idiopathic interstitial pneumonia. It is a disease
of unknown aetiology which develops in the sub-pleural
aspects of the posterior, basal parts of the lungs and be-
comes more extensive over time. On CT scan of the
thorax the lungs show reticular opacities, often associ-
ated with ‘traction bronchiectasis’ and honeycombing
(Figure 3). On histological examination, the features of
usual interstitial pneumonia with characteristic temporal
and spatial heterogeneity are evident [16,17].
It has been known for many years that cough is a clin-
ical feature of IPF. In 1974, Scadding observed: ‘later,
with severe and extensive fibrosis cough, unproductive or
with scanty mucoid expectoration, may be troublesome’
[18]. However, considerable time elapsed before the first
objective study of the cough reflex in IPF was under-
taken by Doherty and coworkers who demonstrated that
cough sensitivity to inhaled capsaicin was increased in
IPF [19]. Furthermore, by binding the chest wall ofymphadenopathy and b, thoracic CT scan showing diffuse
mplained of cough.
Figure 2 Bronchial biopsy from a patient with sarcoidosis
showing typical sub-mucosal granulomata (Haemotoxylin &
Eosin x 20). Photomicrograph courtesy of Drs Allan Dawson and
Paul Griffiths.
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caused by deposition of inhaled capsaicin on more cen-
tral airways as a result of restricted ventilation. A subse-
quent study confirmed that both the two-cough and
five-cough response to inhaled capsaicin was enhanced
in IPF and that such patients also cough in response to
substance P and bradykinin [20]. More recently, Key and
colleagues used a validated cough monitor to show that
patients with IPF had a 24-hour cough frequency that
was similar to patients with cough hypersensitivity syn-
drome and significantly greater than a comparator group
of asthmatics [21]. Interestingly, they also observed thatFigure 3 CT scan of thorax in a patient with IPF showing
typical basal, sub-pleural, honeycomb shadowing and
traction bronchiectasis.cough in IPF is predominantly a daytime rather than
nocturnal symptom and that there was good correlation
between cough frequency and subjective measures of
cough assessed by the Leicester Cough Questionnaire
[21]. There is thus objective evidence from a number of
sources that cough is a troublesome symptom which ad-
versely affects quality of life in patients with IPF [22].
Superficially it appears anomalous that an interstitial
lung disease, which predominantly affects the alveolar
walls in the peripheral lung where sensory innervation is
relatively sparse [23], should cause cough which is gen-
erally associated with diseases such as asthma, COPD
and viral infections, which affect the airways where in-
nervation is more exuberant.
A significant barrier to the methodical study of cough
in IPF is that patients frequently have confounding co-
morbidities which can cause or exacerbate cough. These
include COPD, sinusitis, hypertension treated by angio-
tensin converting enzyme inhibitors and, most import-
antly, gasto-oesophageal reflux disease (GORD). The
latter is a known cause of chronic cough [24] and it has
also been postulated to be a risk factor for the develop-
ment or progression of IPF [16]. The hypothesis that
prolonged, small aspirations of gastric contents may be a
cause of pulmonary fibrosis was proposed by Belcher in
1949 [25]. He also suggested that ‘silent dysphagia’ was a
possible cause of ‘pulmonary lesions of obscure origin’.
This hypothesis has been given further support by recent
objective studies which used 24-hour oesophageal pH
monitoring and oesophageal manometry to demonstrate
that up to 87% of patients with IPF have evidence of acid
reflux which is often asymptomatic [26,27]. Interestingly,
there are also reports of long-term stabilisation of IPF
following treatment with antacid therapy [28].
A recent, preliminary study applied the technique of
combined oesophageal pH and impedance monitoring,
which characterises all reflux episodes regardless of pH, to
show that non-acid reflux also occurs in people with IPF
[29]. When combined with simultaneous, 24 hour cough
recording, the study found that acid suppression therapy
with proton pump inhibitors had no effect on cough and
actually increased the amount of non-acid reflux. These
findings, if confirmed, suggest that acid reflux, per se, is
not the cause of cough in IPF. Gastric juice is a complex
mixture of hydrochloric acid and enzymes such as pepsin,
but it may also contain refluxate from the duodenum
which is alkaline and contains bile acids and pancreatic
enzymes. Potentially, gastroesophageal refluxate contains
a mixture of all these components and may be gaseous as
well as liquid and aspiration of this refluxate could expose
respiratory epithelium to bile salts and enzymes as well as
acid. In-vitro studies have shown that airway epithelial
cells exposed to unconjugated bile salts produce increased
levels of the fibrogenic cytokine Transforming Growth
Figure 4 Idiopathic pulmonary fibrosis, gastroesophageal
reflux and obstructive sleep apnoea: vicious triad or
common associations?
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that airway epithelial cells exposed to pepsin can undergo
epithelial-mesenchymal transformation, a process which
may be associated with the pathogenesis of IPF [31].
The hypothesis that aspiration of gastric contents is an
explanation for both the pathogenesis of IPF and its as-
sociated symptom of cough, has been confounded by a
number of recent clinical and epidemiological observa-
tions. Firstly, that obstructive sleep apnoea (OSA) may
be prevalent in people with IPF [32,33]; secondly, that
OSA is associated with cough [34,35] and finally, the
strong association between OSA with GORD [36]. It is
therefore possible that the three conditions of IPF,
GORD and OSA are linked in what might be described
as a ‘vicious triad’ (Figure 4). However, not all evidence
supports this ‘triad’ as a pathogenetic mechanism. A re-
cent multivariate analysis in 54 patients with fibrosing
interstitial lung disease found no relationship between
the presence or severity of OSA and GORD and that
acid reflux was no more frequent or severe in subjects
with OSA compared to those without [37]. Also, a small
prospective study found no difference in pepsin levels of
exhaled breath condensate between patients with IPF* p < 0.05 
a
Figure 5 a, Concentration of Nerve Growth Factor in bronchoalveolar
normal controls. b, Alveolar macrophages from patients with idiopath
Courtesy of Dr Mat Jones (ref 41).and normal controls [38]. At present, the relationship
between GORD and IPF remains uncertain and it is pos-
sible that the pattern of rapid, shallow breathing, typical
of fibrotic lung in patients with IPF, might actually in-
duce GORD [16].
A different theory for the pathogenesis of cough in IPF
proposes that mechanical distortion of the larger airways
by progressive interstitial fibrosis, so-called ‘traction
bronchiectasis’ (Figure 3) increases cough sensitivity by
altering sensory innervation of the airways [39]. Poten-
tially, this could result from an increase in the number
of rapidly adapting receptors (RARs) which respond to
mechanical stimulation within the airways or, conceiv-
ably, by a destruction of nerves which inhibit cough. A
recent study which tested this hypothesis compared the
effect of mechanical stimulation on cough in people with
IPF and controls. Interestingly, vibration of the chest
wall induced a true cough reflex in the majority of
people with IPF but not controls [40]. Furthermore, the
two-cough response occurred most frequently on stimu-
lation of the posterior, basal parts of the lung, where fi-
brosis is most extensive. Transmission of vibration,
including vocal sound, is increased in pulmonary fibrosis
and is the reason for the typical physical signs of en-
hanced tactile vocal fremitus and vocal resonance. It is
therefore possible that vocalisation or indeed cough it-
self, might enhance cough in IPF by a mechanism of en-
hanced vibration and positive feedback.
As with sarcoidosis, there is some evidence for in-
creased expression of neurotrophins in the lungs of
people with IPF. It has been demonstrated that induced
sputum from such people contains higher levels of NGF
and BDNF compared with normal controls [20] and
BALF from people with IPF contains higher levels of
NGF than controls (Figure 5), [41]. A single immu-
nological study found enhanced expression of NGF
and TrkA in lungs of patients with IPF compared to
other interstitial lung diseases and fibroblastic foci inb
lavage fluid of patients with idiopathic pulmonary fibrosis and
ic pulmonary fibrosis immunostained for nerve growth factor.
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[42]. Thus, despite IPF being a disease of peripheral
lung, these observations raise the possibility that
neurotrophins, generated by the pathological process of
usual interstitial pneumonia, occur in more central air-
ways where they may influence neuronal proliferation
and differentiation.
Treatment of cough in IPF remains problematic for both
patients and physicians, particularly in the later stages of
the condition when it may be associated with increasingly
severe breathlessness. In such cases, palliative therapy
using conventional anti-tussive agents such as opiate-
derived preparations often proves to be of limited benefit,
as does optimal pharmacological treatment of acid reflux.
One small, uncontrolled, open-labeled study found that
cough sensitivity to capsaicin and cough symptom
score was reduced after one month of high-dose oral
corticosteroids suggesting that cough in IPF should be
amenable to pharmacological therapy [20]. In an open-
labeled trial of oral interferon-α, five of 20 patients
reported improvement in cough symptoms [43]. How-
ever, it is well known that cough is a symptom which is
highly influenced by placebo effect; hence the results of
small, open-labeled trials must be interpreted with
caution [44].
A recent double-blind, two-treatment, two-period cross-
over trial comparing thalidomide with placebo demon-
strated a beneficial treatment effect on cough and quality
of life as determined by questionnaires and visual analogue
score [45]. Whilst the authors acknowledge the limitations
of the trial which include small numbers of self-referred
patients with relatively mild IPF who had other possible
causes of cough (70% had acid-reflux and 30% were on
ACE-inhibitors for hypertension), this is the first, placebo-
controlled trial of cough therapy in IPF. Thalidomide is an
interesting drug that may exert its effects through im-
munomodulatory, anti-inflammatory or anti-angiogenic
properties. However, its profile of side-effects which in-
clude constipation, bradycardia, dizziness and in the
longer term, peripheral neuropathy, suggest it may have
a more direct effect on airway nerves. Certainly, the po-
tential anti-tussive effects of thalidomide warrant fur-
ther investigation.
At the present time, physicians are all too often re-
duced to treating the debilitating cough of IPF with opi-
ates as part of an end-of-life pathway. There is thus an
urgent need for better treatments which can only be de-
veloped through our better understanding of the cough
reflex in IPF.
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